The ABL1 Knockout HT29 Polyclonal Cells provide a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the HT29 human colorectal adenocarcinoma epithelial cell line. This loss-of-function model targets ABL1, a non-receptor tyrosine kinase central to signaling pathways governing cell growth, adhesion, migration, and DNA damage responses. The polyclonal format retains population-level heterogeneity, enabling robust and reproducible functional studies in a colorectal cancer context without the constraints of single-cell cloning artifacts.
The host HT29 cell line was established from a primary colorectal adenocarcinoma and serves as a well-characterized epithelial model of colorectal cancer. These cells exhibit key features of tumor biology, including deregulated growth factor signaling, metastatic potential, and chemoresistance, making them a highly relevant system for investigating oncogenic kinase networks and therapeutic vulnerabilities in solid tumors.
ABL1 transduces signals from activated growth factor receptors, such as PDGFR and EGFR, and integrin engagement. Upon stimulation by upstream regulators including Src family kinases, DNA damage, and oxidative stress, ABL1 phosphorylates downstream effectors like Crk, paxillin, and Cbl to modulate actin cytoskeleton remodeling, focal adhesion dynamics, and cell migration. In the nucleus, ABL1 contributes to DNA repair by interacting with Rad52 and BRCA1 and phosphorylating Rad9 and RNA polymerase II, thereby influencing transcriptional response to genomic stress. These activities integrate into broader networks involving the MAPK and PI3K/Akt pathways through adaptor proteins Grb2 and Abi1/2.
In colorectal adenocarcinoma, ABL1 dysregulation is associated with enhanced tumor cell motility, invasion, and resistance to chemotherapy. The ABL1 Knockout HT29 Polyclonal Cells enable precise dissection of ABL1-dependent mechanisms underlying these processes, particularly crosstalk between integrin-mediated adhesion and growth factor receptor signaling. This model allows researchers to examine how ABL1 loss impacts actin dynamics, migratory behavior, and sensitivity to targeted kinase inhibitors, offering insights into solid tumor progression and drug response.
These polyclonal knockout cells are well-suited for a range of experimental applications. Users can validate ABL1 disruption via Western blotting and RT-qPCR, and assess functional consequences through migration/invasion assays, immunofluorescence for actin cytoskeleton visualization, phospho-signaling arrays to profile pathway alterations, and drug sensitivity assays to evaluate chemoresistance. This product supports advanced research in colorectal cancer biology, kinase inhibitor development, and DNA damage-driven tumorigenesis. For further information, please contact Ascent Research.
